Multivalent Pneumococcal Conjugate Vaccine 21 Serotypes Sanofi
Summary
The USPTO issued Patent US12605435B2 to Sanofi Pasteur Inc. for a multivalent pneumococcal polysaccharide-protein conjugate composition covering 21 Streptococcus pneumoniae serotypes. The patent claims conjugates using tetanus toxoid and CRM197 carriers with application in prophylaxis against pneumococcal infection. The patent contains 15 claims and was granted on April 21, 2026.
What changed
USPTO granted Patent US12605435B2 to Sanofi Pasteur Inc. covering a mixed carrier, multivalent pneumococcal conjugate composition comprising capsular polysaccharides from 21 Streptococcus pneumoniae serotypes conjugated to either tetanus toxoid or CRM197.
For pharmaceutical manufacturers and vaccine developers, this patent establishes enforceable IP protection for Sanofi covering broad-spectrum pneumococcal conjugate vaccine formulations. Parties developing competing pneumococcal vaccines should conduct freedom-to-operate analyses to assess potential infringement exposure.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Multivalent pneumococcal polysaccharide-protein conjugate composition
Grant US12605435B2 Kind: B2 Apr 21, 2026
Assignee
SANOFI PASTEUR INC.
Inventors
Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
Abstract
Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
CPC Classifications
A61K 39/092
Filing Date
2024-01-23
Application No.
18419900
Claims
15
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.